MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model

Cancer Science

Volumn 106, Issue 7, 2015, Pages 921-928

  Akita, Shin ^a   Hattori, Noboru ^a   Masuda, Takeshi ^a   Horimasu, Yasushi ^a   Nakashima, Taku ^a   Iwamoto, Hiroshi ^a   Fujitaka, Kazunori ^a   Miyake, Masayuki ^b   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Center for Cerebrovascular Disease   (Japan)

Author keywords

Aminopeptidase N; Angiogenesis; Fully humanized monoclonal antibody; Invasion; Tumor growth

Indexed keywords

AMINOPEPTIDASE INHIBITOR; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; MT 95 4; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR;

A549 CELL LINE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DISEASE COURSE; DRUG SCREENING; IMMUNOLOGY; MALE; MELANOMA, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NONOBESE DIABETIC MOUSE; SCID MOUSE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD13; DISEASE PROGRESSION; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84936985808     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12692     Document Type: Article

References (26)

1. Look AT, Ashumun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989; 83: 1299-307.
2. Ship A, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood 1993; 82: 1052-70.
3. Luan Y, Xu W. The structure and main functions of aminopeptidase N. Curr Med Chem 2007; 14: 639-47.
4. Taylor A. Aminopeptidases: structure and function. FASEB J 1993; 7: 290-8.
5. Dixon J, Kaklamanis L, Turley H et al. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 1994; 47: 43-7.
6. Rangel R, Sun Y, Guzman-Rojas L et al. Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci USA 2007; 104: 4588-93.
7. Yoneda J, Saiki I, Fujii H, Abe F, Kojima Y, Azuma I. Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin). Clin Exp Metastasis 1992; 10: 49-59.
8. Saiki I, Fujii H, Yoneda J et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993; 54: 137-43.
9. Fujii H, Nakajima M, Saiki I, Yoneda J, Azuma I, Tsuruo T. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis 1995; 13: 337-44.
10. Pasqualini R, Koivunen E, Kain R et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000; 60: 722-7.
11. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 2001; 97: 652-9.
12. Fukasawa K, Fujii H, Saitoh Y et al. Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis. Cancer Lett 2006; 243: 135-43.
13. Hashida H, Takabayashi A, Kanai M et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002; 122: 376-86.
14. Ikeda N, Nakajima Y, Tokuhara T et al. Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 2003; 9: 1503-8.
15. Tokuhara T, Hattori N, Ishida H et al. Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 2006; 12: 3971-8.
16. Murakami H, Yokoyama A, Kondo K, Nakanishi S, Kohno N, Miyake M. Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 8674-9.
17. Inoi K, Goto S, Nomura S et al. Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity. Anticancer Res 1995; 15: 2081-7.
18. Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F. Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer 2008; 8: 74.
19. Ichinose Y, Genka K, Koike T et al. Randomized double-blind placebo- controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst 2003; 95: 605-10.
20. Ishida I, Tomizuka K, Yoshida H et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002; 4: 91-102.
21. Worzalla JF, Bewley JR, Grindey GB. Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest New Drugs 1990; 8: 241-51.
22. Guzman-Rojas L, Rangel R, Salameh A et al. Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci USA 2012; 109: 1637-42.
23. Ito S, Miyahara R, Takahashi R et al. Stromal aminopeptidase N expression: correlation with angiogenesis in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 2009; 57: 591-8.
24. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
25. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
26. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.